Poulton Stuart 4
4 · Karyopharm Therapeutics Inc. · Filed Jul 30, 2025
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
2025-07-29$4.37/sh−191$835→ 27,223 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.